US Patent 9,012,501: Claim Scope, Expiration, Orange Book Position and Omega-3 Patent Landscape

US Patent 9,012,501 protects a specific omega-3 pharmaceutical dosage form rather than omega-3 fatty acids generally. The core combination requires a soft gelatin capsule made with Porcine Type A gelatin, a formulation containing at least one omega-3 fatty acid in free-acid form, and a post-aging disintegration result of no more than 30 minutes in purified water at 37°C. Dependent claims add EPA, DHA, dosage strength, coating technologies, and treatment of hypertriglyceridemia.

The patent is most relevant to free-fatty-acid omega-3 products such as Epanova, not to every omega-3 product. Products containing omega-3 ethyl esters, triglycerides, non-porcine capsules, or capsules that fail the specified disintegration test may avoid literal infringement of claim 1.

What patent is US 9,012,501?

US 9,012,501 is a formulation and dosage-form patent titled “Pharmaceutical compositions comprising omega-3 fatty acids.” The patent concerns soft gelatin capsules containing omega-3 fatty acids in free-acid form. The disclosed technology addresses capsule performance after accelerated storage, including maintenance of rapid disintegration following exposure to elevated temperature.

Item	Patent information
U.S. patent	US 9,012,501 B2
Issue date	April 21, 2015
Technology	Omega-3 free-fatty-acid soft gelatin capsules
Core dosage form	Soft gelatin capsule
Capsule material	Porcine Type A gelatin
Active ingredient	One or more omega-3 polyunsaturated fatty acids in free-acid form
Key performance limitation	Disintegration within 30 minutes in purified water at 37°C after three months at 40°C
Therapeutic method	Treatment of hypertriglyceridemia
Relevant commercial product	Epanova and related free-fatty-acid omega-3 formulations
Patent type	Small-molecule formulation and method-of-use patent

The patent claims do not cover a pure omega-3 molecule in the abstract. They require a pharmaceutical dosage form with structural, chemical and performance limitations. The formulation must be inside a soft gelatin capsule, and the capsule must contain sufficient Porcine Type A gelatin to satisfy the aging and disintegration requirement. (U.S. Patent No. 9,012,501, 2015)

What does independent claim 1 of US 9,012,501 require?

Claim 1 has four central limitations:

A pharmaceutical dosage form.
A soft gelatin capsule comprising Porcine Type A gelatin.
A pharmaceutical formulation inside the capsule containing at least one omega-3 polyunsaturated fatty acid in free-acid form.
Capsule disintegration within no more than 30 minutes in purified water at 37°C after storage for three months at 40°C.

The fourth limitation is commercially important. A competitor cannot assess infringement solely by identifying gelatin and omega-3 content. It must evaluate the specified accelerated-storage condition and disintegration test.

The claim does not expressly require EPA, DHA, a particular omega-3 concentration, a coating, a 500-mg or 1,000-mg fill, or a specific daily dose. Those features appear in dependent claims.

The phrase “comprising” generally permits additional ingredients and components. A capsule containing EPA, DHA, excipients, antioxidants, flavoring agents or other formulation materials may still fall within claim 1 if every required limitation is present.

How broad is the Porcine Type A gelatin limitation?

The gelatin limitation is narrower than a generic “soft gelatin capsule” requirement. Claim 1 requires Porcine Type A gelatin. Claim 14 narrows the formulation further by requiring that the gelatin consist essentially of Porcine Type A gelatin.

This creates several potential design-around categories:

Capsule construction	Claim 1 risk
Porcine Type A gelatin	High, subject to disintegration testing
Porcine gelatin of a different type	Fact-dependent
Bovine gelatin	Lower literal risk
Fish gelatin	Lower literal risk
Plant-based capsule	Lower literal risk
Hydroxypropyl starch or HPMC capsule	Lower literal risk
Mixed gelatin system containing Porcine Type A gelatin	Potentially high
Porcine Type A gelatin with a non-gelatin capsule shell	Depends on the dosage-form construction

The claims do not make porcine gelatin alone sufficient for infringement. The free-acid omega-3 requirement and the aged disintegration result must also be met.

What omega-3 ingredients are protected?

Claims 4 through 6 identify EPA and DHA:

Claim 4 covers EPA in free-acid form.
Claim 5 covers a combination of EPA and DHA in free-acid form.
Claim 6 covers DHA in free-acid form.

The chemical forms identified in the claims are:

EPA: 5,8,11,14,17-eicosapentaenoic acid.
DHA: 4,7,10,13,16,19-docosahexaenoic acid.

The claims are directed to free fatty acids. That distinction matters because major prescription omega-3 products use different chemical forms.

Omega-3 form	Relevance to US 9,012,501
EPA free acid	Within the express scope of claim 4 when other limitations are met
DHA free acid	Within the express scope of claim 6 when other limitations are met
EPA/DHA free-acid mixture	Within the express scope of claim 5 when other limitations are met
Icosapent ethyl	Not the claimed free-acid form
Omega-3 ethyl ester mixture	Generally outside the claimed free-acid limitation
Omega-3 triglycerides	Generally outside the claimed free-acid limitation
Mixed formulations containing some free acid	Requires analysis of the full formulation and claim construction

Claims 2 and 3 create concentration tiers requiring at least about 50 wt% or at least about 90 wt% omega-3 free acid. The open language of claim 1 is broader because it does not prescribe a minimum concentration.

What formulations and coatings are protected?

Claims 7 through 13 cover coated capsules and several release profiles.

Claim	Protected feature
7	Capsule with an external coating
8	Coating that delays release after oral administration
9	Time-dependent, but not pH-dependent, release coating
10	Coating resistant to dissolution in a pH-dependent manner
11	Delayed release until after passage through the stomach
12	Neutral polyacrylate coating
13	Poly(ethylacrylate-methylmethacrylate) coating

Claim 7 is broad relative to claims 9, 10 and 12. It does not require a particular polymer or release mechanism. A coating that delays release may implicate claim 7 even if it does not use the specific neutral polyacrylate identified in claim 12.

Claims 9 and 10 describe different release concepts. Claim 9 focuses on time-dependent release without pH dependence. Claim 10 addresses pH-dependent dissolution resistance. Claim 11 is functional and gastrointestinal in nature, requiring delay until after stomach passage.

The coating claims increase infringement risk for enteric or delayed-release free-fatty-acid omega-3 capsules using soft porcine gelatin shells. A product that uses an uncoated capsule may still implicate claims 1 through 6 and 14 through 20.

What dosage strengths and treatment methods are claimed?

Claims 15 through 17 cover the amount of formulation inside the capsule:

About 100 mg to about 2,000 mg under claim 15.
About 500 mg under claim 16.
About 1,000 mg under claim 17.

Claims 18 through 20 cover treatment of hypertriglyceridemia:

Claim 18 covers administering an effective amount.
Claim 19 specifies about 1 g to about 8 g per day.
Claim 20 specifies about 4 g per day.

The method claims require use of the claimed dosage form. Administering an omega-3 product that lacks the Porcine Type A capsule or free-acid formulation limitations would not literally satisfy the incorporated dosage-form limitations.

When does US 9,012,501 lose exclusivity?

The patent claims alone do not establish the exact expiration date. U.S. patent term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers and any patent-term extension. The controlling date must be taken from the USPTO patent-term record rather than calculated from the issue date. (35 U.S.C. § 154)

The practical exclusivity analysis should separate three dates:

Date type	Business significance
Base patent-term date	Statutory end of the 20-year term
Adjusted expiration date	Adds qualifying USPTO examination delay
Orange Book or regulatory exclusivity date	May differ from patent expiration
Commercial availability date	Depends on FDA approval and product marketing

A patent expiration date does not by itself establish generic launch permission. Regulatory exclusivity, other listed patents, litigation settlements, pediatric extensions, injunctions and product-specific FDA requirements can affect entry.

What is the FDA and Orange Book status of the related product?

Epanova was approved by the FDA in 2014 for severe hypertriglyceridemia. It contained omega-3 carboxylic acids, including EPA and DHA in free-acid form, and was developed as a prescription product distinct from omega-3 ethyl ester products. (FDA, 2014)

AstraZeneca later discontinued the Epanova development and commercial program after the STRENGTH cardiovascular-outcomes study failed to show the intended benefit. The FDA subsequently reflected the product’s discontinued status in its regulatory records. The discontinuation reduced the commercial value of the patent estate, although it did not automatically invalidate the patent or eliminate possible claim relevance to later products.

For Orange Book analysis, the relevant questions are:

Whether NDA 206500 remains listed as active or withdrawn.
Whether US 9,012,501 was listed against that NDA.
Whether the patent listing remains operative after product discontinuation.
Whether a later applicant would need to address the patent through a Paragraph IV certification.
Whether other formulation or manufacturing patents remain listed.

The FDA Orange Book is the controlling source for listed patents and exclusivity associated with approved drug products. Patent ownership and Orange Book listing are separate issues. A patent may exist without being listed, and an Orange Book listing does not establish ultimate infringement validity. (FDA, 2024)

How does US 9,012,501 compare with Vascepa and Lovaza patents?

US 9,012,501 occupies a different technical position from the principal patents associated with Vascepa and Lovaza.

Product	Active form	Primary patent risk relative to US 9,012,501
Epanova	Omega-3 carboxylic acids, including free acids	Directly relevant
Vascepa	Icosapent ethyl	Free-acid limitation creates a material distinction
Lovaza	Omega-3-acid ethyl esters	Generally outside the free-acid limitation
Omtryg	Omega-3-acid ethyl esters	Generally outside the free-acid limitation
Generic fish-oil products	Variable triglyceride, ester or free-acid content	Product-specific analysis required

Vascepa litigation primarily concerned icosapent ethyl patents and method-of-use claims for cardiovascular risk reduction. Those disputes do not establish infringement of a free-fatty-acid soft-capsule patent. (Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., 2020)

The relevant competitive threat is therefore a follow-on prescription product using EPA or DHA free acids in a soft porcine gelatin capsule, especially one using aged-disintegration specifications and delayed-release coatings.

Which companies may face Paragraph IV or generic-entry risk?

A generic applicant seeking approval for a product that references a listed free-acid omega-3 product may need to address relevant Orange Book patents through Paragraph IV certifications. The risk profile depends on the proposed capsule and formulation.

High-risk product profile

A proposed generic is most exposed if it has:

A soft capsule made with Porcine Type A gelatin.
EPA or DHA in free-acid form.
At least 50 wt% or 90 wt% omega-3 free acid.
A 500-mg or 1,000-mg fill.
A neutral polyacrylate or similar delayed-release coating.
A 4-g-per-day dosing regimen.
A hypertriglyceridemia indication.

Lower-risk product profile

Risk is lower where the product uses:

Ethyl ester or triglyceride omega-3s.
Non-porcine gelatin or a non-gelatin shell.
No external coating.
A formulation that fails the specified post-aging disintegration test.
A different therapeutic indication without reliance on the claimed method.

A Paragraph IV certification would likely trigger the patent-holder’s ability to file an infringement action and obtain a 30-month regulatory stay under the Hatch-Waxman framework, subject to the statutory requirements and Orange Book status. (21 U.S.C. § 355)

What is the patent strength of US 9,012,501?

The patent has meaningful technical specificity but a relatively narrow product footprint.

Strengths

Claim 1 combines composition, capsule material and performance testing.
The post-aging disintegration limitation may be difficult to design around while retaining equivalent product performance.
EPA and DHA free-acid formulations are expressly addressed.
Dependent claims create coverage for common fill amounts and delayed-release configurations.
Method claims connect the dosage form to hypertriglyceridemia treatment.

Weaknesses

The claims do not broadly cover all omega-3 products.
The Porcine Type A requirement provides a clear non-porcine design-around path.
The free-acid limitation distinguishes the patent from ethyl ester and triglyceride products.
The disintegration limitation may create proof and reproducibility issues.
The patent’s commercial value is affected by the discontinuation of Epanova.
Claim 18 may face method-of-use issues if the accused product labeling does not encourage the claimed treatment.

The strongest infringement theory would involve a marketed free-fatty-acid EPA/DHA product using the same capsule material, coating architecture and accelerated-storage performance. The weakest theory would involve an ethyl ester or triglyceride product in a non-porcine capsule.

What litigation and settlement issues affect the patent?

The supplied claims do not establish a Paragraph IV notice, ANDA litigation, settlement agreement, injunction or terminal disclaimer. Those matters are external to the patent claims and must be determined from USPTO records, FDA Orange Book data, PACER filings and applicable district-court dockets.

The principal litigation questions are:

Whether the patent was listed for Epanova.
Whether an ANDA applicant filed a Paragraph IV certification.
Whether the patent holder filed an action within the statutory period.
Whether the parties entered a delayed-launch or license settlement.
Whether any continuation or divisional patent remains enforceable.
Whether the patent has been disclaimed, reexamined or challenged at the Patent Trial and Appeal Board.

No biosimilar pathway applies. Omega-3 fatty-acid products are small-molecule drugs, not biologics. Competitive entry would proceed through an ANDA, a 505(b)(2) application or an independent NDA, not through a biosimilar application under section 351(k) of the Public Health Service Act.

What manufacturing and geographic barriers exist?

The geographic scope of US 9,012,501 is the United States. Corresponding foreign family members, if granted, must be analyzed separately by jurisdiction. Patent expiration, prosecution history, claim amendments and validity outcomes can differ in Europe, Japan, Canada and other markets.

Manufacturing barriers include:

Sourcing Porcine Type A gelatin with consistent shell performance.
Maintaining capsule disintegration after accelerated aging.
Controlling oxidation of EPA and DHA.
Filling high-load free-fatty-acid formulations into soft capsules.
Applying a uniform neutral polyacrylate coating.
Demonstrating dissolution and release specifications.
Matching the reference product’s stability profile.

These barriers may raise development costs even where a generic applicant designs around one or more patent limitations.

Key Takeaways

US 9,012,501 is a formulation patent focused on free-acid omega-3s in Porcine Type A soft gelatin capsules.
Claim 1 requires a post-aging disintegration result of no more than 30 minutes at 37°C in purified water.
EPA, DHA, high active loading, capsule fill amounts and delayed-release coatings are covered by dependent claims.
The patent is more relevant to Epanova-type products than to Vascepa, Lovaza or Omtryg.
Ethyl ester, triglyceride, non-porcine and non-gelatin products have potentially strong design-around positions.
Exact patent expiration requires the USPTO term record, including patent-term adjustment and any terminal disclaimer.
No biosimilar pathway applies because the products are small-molecule omega-3 drugs.
The principal commercial risk is a follow-on free-acid EPA/DHA product using a porcine soft capsule and comparable delayed-release performance.

FAQs

Does US 9,012,501 cover Vascepa?

Not on the face of the supplied claims. Vascepa contains icosapent ethyl, while US 9,012,501 requires at least one omega-3 fatty acid in free-acid form. The capsule and formulation would also need to satisfy the remaining claim limitations.

Does the patent cover fish-oil softgels sold over the counter?

Usually not automatically. The product would need to contain an omega-3 free acid, use a soft capsule comprising Porcine Type A gelatin and meet the specified post-aging disintegration requirement. Many over-the-counter products use triglyceride or ethyl ester forms.

Can a generic avoid the patent by using bovine gelatin?

Potentially, but the analysis depends on claim construction and the full formulation. Bovine gelatin does not literally satisfy a requirement for Porcine Type A gelatin, but other patents or infringement theories may remain relevant.

Is the 30-minute disintegration requirement a product specification or a patent limitation?

It is a claim limitation. A product that otherwise matches the capsule and free-acid requirements may still avoid literal infringement if it does not satisfy the specified disintegration condition, subject to testing methodology and claim construction.

Does withdrawal of Epanova invalidate US 9,012,501?

No. FDA product withdrawal and patent validity are separate matters. Withdrawal can reduce commercial value and affect Orange Book strategy, but it does not by itself cancel, invalidate or expire the patent.

References

Food and Drug Administration. (2014). Epanova approval history and prescribing information, NDA 206500. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. U.S. Department of Health and Human Services.
Food and Drug Administration. (2021). NDA 206500 Epanova regulatory and discontinuation records. U.S. Department of Health and Human Services.
U.S. Patent No. 9,012,501. (2015). Pharmaceutical compositions comprising omega-3 fatty acids. United States Patent and Trademark Office.
21 U.S.C. § 355. (2024). New drugs and abbreviated new drug applications.
35 U.S.C. § 154. (2024). Contents and term of patent; provisional rights.
Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., 819 F. App’x 932 (Fed. Cir. 2020).

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0403247	Feb 13, 2004

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	047799	⤷ Start Trial
Austria	E457720	⤷ Start Trial
Australia	2005215198	⤷ Start Trial
Brazil	PI0507473	⤷ Start Trial
Canada	2555064	⤷ Start Trial
China	107690770	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,012,501

Summary for Patent: 9,012,501